Alembic Pharmaceuticals’s joint venture Aleor Dermaceuticals has received an approval from the US Food & Drug Administration for its Abbreviated New Drug Application Desonide ointment, 0.05%. The approved ANDA is therapeutically equivalent to Perrigo New York, Inc’s ointment. The drug is a low-potency corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. The ointment has an estimated market size of $13 million in calendar 2018, according to IQVIA. Shares of Alembic closed 1.8 per cent higher at ₹546.95 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.